2024 AAIC Poster
2024 AAIC Poster:
INTERCEPT-AD: Understanding the Patient Experience and Expectations for Treatment Through Qualitative Interviews Among Trial Participants with Early Alzheimer’s Disease
and Their Study Partners
2024 AAIC Poster
2024 AAIC Poster:
Sabirnetug (ACU193) Lowers CSF Levels of Synaptic Biomarkers in INTERCEPT-AD Phase 1 Study in Early AD
2024 AAIC Poster
2024 AAIC Poster:
INTERCEPT-AD: Development and Qualification of a Highly Sensitive Immunoassay Detecting Total Sabirnetug (ACU193) in Human CSF
2024 AAIC Poster
2024 AAIC Poster:
INTERCEPT-AD: A Gender Analysis of the Phase 1 Experience Among Trial Participants with Early Alzheimer’s Disease and Their Study Partners
2023 CTAD Poster
2023 CTAD Poster:
Recruitment and Eligibility of a Diverse Study Population in INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer’s disease.
2024 ADPD Poster
2024 ADPD Poster:
Target Engagement in INTERCEPT-AD: Development of a Novel Assay Measuring Sabirnetug (ACU193)-Amyloid Βeta Oligomer Complexes in Human CSF.
2024 AAN Poster
2024 AAN Poster:
A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes.
2023 ADPD Poster
2023 ADPD Poster:
Binding of Soluble Amyloid Beta Oligomer Species to Human IPSC-derived Excitatory Neurons Assessed Using a Panel of AB Antibodies.
2023 CTAD Poster
2023 CTAD Poster:
INTERCEPT-AD: ACU193 CSF pharmacokinetics in early Alzheimer’s disease.
2023 CTAD Poster
2023 CTAD Poster:
Incorporating the Study Participant’s Voice into Early Development of ACU193 for Early Alzheimer’s Disease: A Qualitative Interview Study Following Participation in the INTERCEPT-AD Study.
